Latest fiscal year 2023 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2023, AXIM BIOTECHNOLOGIES, INC. reported revenue of $0M, up 345.3% year over year. Operating margin was -6961.0% and net margin -20395.0%, on a free-cash-flow margin of -2607.7% with capital expenditure at 0.0% of revenue. Every figure is computed directly from AXIM's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2023 | $0M | -6961.0% | -20395.0% |
| FY2022 | $0M | -52425.6% | -70343.1% |
| FY2021 | $0M | -23114.5% | -26517.2% |
| FY2020 | $0M | n/a | n/a |
| FY2019 | $1M | -388.9% | -806.5% |
How does AXIM compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.